James Basta is CLO & VP at Intellia Therapeutics, Inc. (NTLA). They have made 8 open-market trades across 1 company since 2023, most recently 2026-03-02.
CIK 0001792726
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 156,794 | $1.9M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NTLA | SELL | 2026-03-02 | 2026-03-03 | $13.78 | $17K | -8.7% | -6.1% | -1.9% |
| NTLA | SELL | 2026-01-05 | 2026-01-07 | $9.21 | $96K | +19.7% | +14.6% | +26.5% |
| NTLA | SELL | 2025-03-04 | 2025-03-04 | $8.99 | $23K | -2.8% | -26.7% | -23.8% |
| NTLA | SELL | 2025-01-03 | 2025-01-07 | $12.18 | $172K | -17.4% | -15.9% | -45.7% |
| NTLA | SELL | 2024-03-04 | 2024-03-05 | $32.99 | $152K | -8.2% | -19.0% | -23.7% |
| NTLA | SELL | 2024-01-03 | 2024-01-05 | $29.46 | $224K | -10.4% | -11.9% | -11.4% |
| NTLA | SELL | 2023-03-02 | 2023-03-03 | $43.88 | $48K | -5.8% | -14.5% | -12.1% |
| NTLA | SELL | 2023-01-04 | 2023-01-06 | $37.21 | $42K | -13.2% | +14.3% | -6.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.